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Background: In patients treated with oral anticoagulants, subcutaneous injections of anti-tetanus vaccine are
usually recommended to reduce the risk of bleeding, although the effectiveness of the vaccine has only been
proven for intramuscular injection. The objective of this study was to compare the safety and efficacy of
intramuscular and subcutaneous injections of tetanus-diphtheria vaccine in patients treated with oral
anticoagulants.
Methods/design: We present a prospective, double blinded, clinical trial comparing two groups of patients with
oral anticoagulants: one group was administered tetanus-diphtheria vaccine by intramuscular injection, while the
other was administered the same vaccine by subcutaneous injection. Allocation to each group was randomized
and the duration of the study was six years.
Study population: all patients treated with oral anticoagulants, who had been administered with at least one dose
of vaccine, at 15 Health Centres in Vigo (Spain), and who agreed to participate in the study. The sample size was
115 patients in each group. The main variables for the safety analysis were the measurement of the brachial
diameter, the appearance of basic injuries at the vaccine administration site, the appearance of pain and systemic
reactions. The variable used for the efficacy analysis was a significant increase in the titres of anti-tetanus toxoid
antibodies.
An Intention-to-treat analysis will be performed. Details will be classified according to the administration route, while within
each group a 3-tiered stratification will be defined by the administered number of doses. As a measure of association,
relative risk will be estimated; the reduction of relative risk will also measured. For safety and to control the confounder
effect, a logistic regression analysis will be carried out. As a measure of impact the reduction of absolute risk in relation to
the total number of patients to be treated and the Number Needed to Treat will be estimated.
CONSORT 2010 guidelines were applied for reporting parallel group randomised trials.
Discussion: The most significant difficulties on the project are related to the large number of participating centres,
required to obtain a viable study population sample size, and the coordination given the scattering of the centres and
researchers.
Trial registration: ISRCTN69942081.
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Despite its low incidence, tetanus is a major public health
problem with a high fatality rate (40-50%) [1]. The annual
register of cases has slowly been descending over the last
10 years, with an average of 25 cases/year in Spain (inci-
dence of 0.06 cases per 100,000 population) [1]. In Galicia
(Spain) during the last 5 years, on average, there have been
3 cases reported per year [2].
Tetanus is a disease that can be fully controlled, as it
can be prevented by vaccination. However, it cannot be
eradicated, because Clostridium tetani is a widely distrib-
uted microorganism in the environment. Immunization is
highly effective [1], providing long-term protection and is
recommended for the whole population in general, even
though booster doses are required to maintain immunity,
after the first vaccination [3].
Most cases of tetanus occur in previously unvaccinated
adults, especially among those over 60 years of age [4].
Seroprevalence studies demonstrate that immunity from
tetanus is higher than 95% in Spanish cohorts born after
1982, decreasing progressively in cohorts born prior to
this date; for example, in the 1957–1966 cohort immunity
is only around 55% [1]. Studies of the elderly have re-
ported seroprevalence of 7.7% in those over 70 years of
age [5]. In Spain, the fact that most adults of over 50 years
of age have not been vaccinated or have only been incom-
pletely vaccinated is probably because the immunization
calendar for the five-dose course of tetanus vaccine was
not introduced until the early 1970s [6].
With any wound, the need to administer active immu-
nization (tetanus toxoid) alone or jointly with passive
immunization (tetanus immunoglobulin) depends on the
type of wound, the probability of contamination with tet-
anus bacillus, and also on the knowledge of the patient’s
vaccination history [1]. The current recommended treat-
ment is the combined tetanus-diphtheria vaccine (presen-
tation for adults) or intramuscular Td vaccine [1-3].
Most anticoagulated patients in primary care consulta-
tions are seen due to auricular fibrillation and, on average,
they are over 56 years of age [7,8]. Hence, vaccination
coverage is probably low [9].
In anticoagulated patients, because of the hypothetical
risk of bleeding after injection, use of the intramuscular
route has been traditionally discouraged, with the sub-
cutaneous route being recommended, even for vaccines
that are routinely administered intramuscularly, as for
tetanus [10-12]. Indeed, in the literature, a few cases of
major bleeding complications have been published [13].
Yet, although there is no uniformity of results in studies
comparing the effectiveness of the two routes [14,15], vac-
cine efficacy studies have used the intramuscular route
[1,10,14], and subcutaneous administration may be less ef-
fective compared to intramuscular administration. More-
over, for most vaccines, local adverse reactions are morefrequent with subcutaneous administration than with the
intramuscular route [14-16].
The safety of the intramuscular route for the hepatitis
B [17] and influenza vaccines [18], which are also adminis-
tered intramuscularly, has been demonstrated in patients
with alterations in coagulation and, consequently, the
2006 CDC guidelines recommend intramuscular injec-
tion for the tetanus-diphtheria (Td) vaccine depending
on medical criteria [10].
We have not found any study in the literature that as-
sesses the safety and efficacy of intramuscular (IM) and
subcutaneous (SC) administration for the Td vaccine in
patients treated with oral anticoagulants.
The objective of this study was to compare the safety
and efficacy of the intramuscular and subcutaneous routes
of administration for tetanus-diphtheria (Td) vaccine in
patients treated with oral anticoagulants, and to verify
the hypothesis that IM administration is safer and has
greater efficacy.
Methods/design
We present a prospective, double-blind, phase IV clinical
trial with two parallel groups and layered randomized
assignment. Each one of these parallel groups was given
doses of the corresponding tetanus vaccine, either intra-
muscularly (Group 1) or subcutaneously (Group 2), as
shown in Figure 1. The layers were defined by the num-
ber of doses of the corresponding anti-tetanus injections
(one, two or three), in each tier. This trial was only de-
signed for the vaccination of the general anticoagulated
population, and not for situations with wounds.
Patients
The following inclusion criteria were applied to all pa-
tients who were undergoing monitored treatment with
oral anticoagulants at 15 Health Centres within the Vigo
Primary Care Area.
Inclusion criteria
 Patients treated with oral anticoagulants, for whom
administering of at least one dose of anti-tetanus
vaccine was indicated. This criterion was for those
patients whose vaccination status was unknown,
uncertain, or if they were clearly not vaccinated.
 After being duly informed of the nature of the trial,
patients were included if they gave written consent
to be vaccinated and participate in the study.
Exclusion criteria
 Severe local reaction to previous doses with the
whole circumference of the injected limb being
affected.
Figure 1 Summary of trial design.
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doses.
 Severe anaphylactic reaction due to previous doses
or any of the components.
 Poor haematological control (International
Normalized Ratio [INR] > 4) in the last 2 months.
 Serious illness, terminal stages of diseases,
immobilized, adversely affected by chronic pathology
or immunosuppressive states.
 Pregnant or breast-feeding women.Sample size
Assuming that for the IM route the percentage of local
side effects is 30% [11,15,16] and expecting an increase of
18% [15] in local secondary effects for the alternative
route (SC), using a bilateral approach, with a 95% confi-
dence interval, a beta risk of 0.20 requires 115 patients in
each group. Taking into account the possible 15% loss in
information, the final sample size was 135 patients in each
group. With this sample size, it was estimated that a 3 UI/
ml mean difference in antibody levels could be detected.
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Patients were recruited at the primary care centres by
their family doctors. During the first visit, the doctor
assessed the vaccination state of the patient, taking into
account the vaccination records in the patient’s medical
history, or by interviewing the patient if such informa-
tion was not available. According to the number of doses
received and the date of the last dose, the doctor was able
to determine if the patient was properly vaccinated (and, if
so, the patient was excluded from the study), or whether
they needed to be given a booster dose, or to start or
complete adult primo-vaccination. The guidelines used for
applicable vaccination were those recommended by the
Spanish Ministry of Health in 2008 [1,3,4]:
For complete primo-vaccination, and less than 10 years
since the last dose: nothing (not included in the study).
a) For complete primo-vaccination, and more than
10 years since the last dose: 1 booster dose.
b) In cases of no previous vaccination: complete
primo-vaccination with three doses separated by
1–2 months between the first two, and 6–12 months
between the second and third, with subsequent
booster doses every 10 years. If primo-vaccination
had been started prior to the beginning of the study,
the patient was administered doses according to the
standard schedule.
c) In cases of incomplete primo-vaccination:
a. One dose if the patient already had been
administered two doses, and the last dose was
more than a year earlier.
b. Two doses, separated by six months, if the
patient had one dose administered more than a
month earlier.When vaccination status was unknown or doubtful,
primo-vaccination was started.
After assessing if the patient fulfilled all inclusion criteria,
and none of the exclusion criteria, they were invited to par-
ticipate in the study and, if they agreed to sign informed
consent, were included in one of the tiers, according to the
corresponding (allocation ratio 1:1) vaccine dose (one, two
or three). The patients were given an appointment to have
an INR test and, if the score was less than 4, a blood sam-
ple was taken to determine anti-tetanus antibodies, and a
dose of vaccine was immediately administered, so that the
patient could proceed to the corresponding nursing con-
sultancy. The nurse was responsible for requesting from
the randomization centre, by telephone, the administration
route to which the patient had been assigned. The patient
was not informed of the administration route used. Pa-
tients requiring more than one dose received all doses via
the same route, and were given appointments in relation to
the interval and number of corresponding doses.The doctor was blinded to the administration route and
also to the follow-up appointments (1, 2, 14 and 30 days)
after each dose of the vaccine to detect any side effects.
On the first visit, after administering the vaccine, and
at 30 days after the last dose of anti-tetanus vaccine (ATV),
the antibody titre was determined for all patients using en-
zymatic immunoanalysis.
The systematic physical examination at each visit in-
cluded the following aspects:
 General appearance.
 Temperature
 Arterial blood pressure.
 Measurement of the brachial perimeter at the height
of the deltoid on the first visit, and at the site of
inoculation after vaccination.
 Examination and palpation of the injection site
looking for basic injuries.
 Homolateral axillary palpation of the injection site.
 Any examination required due to the emergence of
a general and/or unexpected side effect.
Laboratory analysis
 Determination of INR through the capillary
technique with a reflectometer.
 Determination of antitoxoid tetanus antibodies by
enzymatic immunoanalysis in a centralized
Laboratory (Barcelona).
Data collection
The first patient was included in January 2009, with an ini-
tial 24-month forecast for the period of inclusion, which
subsequently had to be extended to 72 months, due to dif-
ficulties in reaching the predetermined sample size
All data were recorded on a case report form (CRF)
designed for that purpose. A specific database was cre-
ated to upload the data.
A training workshop was held for all researchers par-
ticipating in the clinical trial regarding techniques, col-
lection of data and measurement of study variables prior
to the beginning of the study.
Premature abandonment by a patient
The researcher determined the primary reason for pre-
mature abandonment by the patient and recorded this
information on the CRF. Patients could be prematurely
removed from the study for one of the following reasons:
side effects in primo-vaccination; patient withdrew con-
sent; loss of follow-up; administrative problems or death.
For patients who could not be contacted and missed
the follow-up, the researcher documented the steps taken
to contact the patient.
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The main analytical safety variables were:
1. Measurement of the brachial perimeter in
centimetres.
2. Appearance of basic injuries (redness, swelling, heat,
granulomas, haematoma) in the area of
administration of the vaccine, axillary nodes, and the
appearance of pain measured with the visual
analogue pain scale.
3. The emergence of general symptoms (fever, malaise,
headache, weakness, arthralgias).
4. The appearance of any serious adverse effect: one
that was fatal or posed danger to patient’ life, ended
in disabilities or required hospitalization.
For each route of administration, the main variable
used in the efficacy analysis was the increase in anti-
tetanus antibodies following vaccination.
Statistical analysis
Descriptive, statistical analysis will be used to classify the
data into two groups, according to the route of adminis-
tration, while within each group a 3-tiered stratification
will be defined by the administered number of doses.
The quantitative data will be summarized by estimating
the arithmetic mean and median as measures of central
tendency, as well as the standard deviation as a measure
of dispersion. For qualitative variables, proportions with
95% confidence intervals will be estimated.
After checking the conditions of application and as-
suming an alpha error of 0.05, the Chi-squared test will
be used to determine the statistical differences between
the qualitative variables in the two study groups. Prior
checking of all the criteria for application will be carried
out before the Student’s-t test (0.05 alpha) is used to
examine the levels of significance in the differences in
quantitative variables for independent data. If the condi-
tions of application were not met, the non-parametric
Mann–Whitney U test will be used. The Student’s t test
for paired data will be employed for paired quantitative
variables.
As an association measurement, relative risk will be
estimated with a 95% confidence limit, according to the
method of Mantel and Fleiss. In addition, as a further as-
sociation measurement, relative risk reduction will be
calculated with a 95% confidence interval. For the safety
study and to control the effect of different confounding
covariables, a logistic regression analysis will be simul-
taneously performed.
As a measurement of impact, the reduction of absolute
risk (RAR) and the Number of patients Needed to be
Treated (NNT) to prevent an event will be calculated
with 95% confidence intervals.An Intention-to-treat (ITT) analysis will be carried
out, even when it was highly or totally improbable that
crossing occurs within groups, because this intervention
is predictably limited to a particular moment.Allocation and masking
The randomization unit is the individuals participating
in the trial. A random allocation is made within a 3-tiered
stratification based on the number of doses of vaccine
required for successful immunization (1, 2 or 3 doses).
Within each tier, simple randomization is performed by
spreadsheet, in an attempt to control the confounder ef-
fect of the number of doses.
Mapping is performed by the Fundación Galicia Sur
(EOXI Vigo) to which all researchers were given tele-
phone access.
Information concerning the randomization process
remained confidential until the end of the study. It is the
responsibility of each researcher to ensure that there is a
specific procedure that allowed for the opening of the
code in case of emergency, with immediate communica-
tion to the randomization centre.
The route of administration is masked in the database to
prevent the team performing the computer analysis from
discovering the route that corresponded to each group.
Loss of masking only occurred in cases of emergency
for the patient and at the conclusion of the study.Ethical aspects and confidentiality of data
In compliance with the Helsinki Declaration, it was the
responsibility of the researcher to inform the patients of
their participation in a clinical study, and to clarify that
this participation was voluntary and did not imply any
change in treatment or medical care received by partici-
pating patients, as compared to that received by patients
who did not participate. The researcher then had to ob-
tain written, informed consent from patients before they
could be included in the study.
The highest levels of confidentiality and professional
conduct were always maintained and the existing na-
tional legislation on data protection was respected. The
patients’ identities were encoded in the study documents
and only duly authorized personnel had access to identi-
fiable personal data, when data verification procedures
required that this information had to be inspected.
It was the responsibility of the researcher to inform
the patients in a clear and concise way that their data
would be incorporated into a computerised database,
which would only be used for clinical research purposes,
and that the patient could not be identified in that data-
base. In the database, the patients were each assigned an
internal code number by the randomization centre, which
remained unknown to the researcher, so that their clinical
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able person.
Likewise the CRF data were treated confidentially. The
name of the patient was hidden and could only be iden-
tified through a number corresponding to the researcher
code and the patient code.
This project respected ethical principles for medical
research involving human subjects, as set out in the
World Medical Association Declaration of Helsinki, to-
gether with the clinical research rules of the Spanish Re-
search Act Regulations, and was granted permission by
the Clinical Research Ethics Committee with approval ob-
tained on 07/06/2007 with number 2007/089 (N° EudraCT
2007-001073-29), which was subsequently modified and
extended on 13/04/2009, 10/09/2009 and 13/12/2010 by
successive expansion in the number of participating health
centres (from the initial 6 to 15), to improve recruitment
of patients.
During the development of the study, there was regu-
lar monitoring that the information contained in each
patient’s CRF was complete and regularly updated, and
that the required good clinical practice was being main-
tained in adherence with the Protocol and the follow-up
procedures.
The original documents of each participating patient
in the study, consisting of annotations made during each
visit and the signed original of informed consent forms,
were maintained by the researchers.
Discussion
This present clinical trial was designed to demonstrate
that the administration of tetanus vaccine via the intra-
muscular route is safe and has greater efficacy than the
subcutaneous route in anticoagulated patients, which
would make it possible to routinely recommend this route
in these patients. This is relevant because the prevalence
of patients treated with oral anticoagulants is increasing,
even at younger ages, and anti-tetanus vaccine, the only
one with universal indication, is still the only measure
with proven efficacy for preventing new cases of tetanus.
There are inherent difficulties in conducting clinical
studies, with a variety of possible eventualities that affect
researchers, patients and the actual structure and
organization of the centres. To these handicaps, must
be added the following particular characteristics of pri-
mary care: the extra effort required for coordination
given the scattering of the centres and researchers; the
accessibility of care at this level, at least in Spain, which
causes great pressure on health and welfare services
with little control over the distribution of daily work,
with a resulting conflict regarding the space and time
available for research activities.
In addition, there are problems relating to the study it-
self. For example, as the number of anticoagulated patientswith vaccination criteria is low, to obtain a viable study
population sample size required the participation of a
large number of centres, which hindered the monitoring
and coordination of the project. Finally, the large num-
ber of participating centres increased the need for spe-
cial care in keeping doctors and patients blind to the
route of vaccination.
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